{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:05:07Z","timestamp":1787843107127,"version":"build-2784847793"},"reference-count":86,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.mayocp.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T20:07:32Z","timestamp":1564171652000},"page":"1865-1878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy"],"prefix":"10.1016","volume":"94","author":[{"given":"Anastasia","family":"Zekeridou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda A.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrc1255","article-title":"Paraneoplastic neurological degenerations: keys to tumour immunity","volume":"4","author":"Albert","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","article-title":"CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity","volume":"49","author":"Yu","year":"2001","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.02.003_bib3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/3315","article-title":"Tumor-specific killer cells in paraneoplastic cerebellar degeneration","volume":"4","author":"Albert","year":"1998","journal-title":"Nat Med"},{"issue":"6167","key":"10.1016\/j.mayocp.2019.02.003_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.003_bib5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0025-6196(12)62189-2","article-title":"Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume","volume":"65","author":"Hetzel","year":"1990","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.mayocp.2019.02.003_bib6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens\u2014pathogenesis, associated disorders and antibody testing","volume":"8","author":"Lancaster","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-065X.2012.01144.x","article-title":"Neural antigen-specific autoimmune disorders","volume":"248","author":"Iorio","year":"2012","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.mayocp.2019.02.003_bib8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"14","key":"10.1016\/j.mayocp.2019.02.003_bib9","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-14-0652","article-title":"Neural autoantibody clusters aid diagnosis of cancer","volume":"20","author":"Horta","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6024","key":"10.1016\/j.mayocp.2019.02.003_bib11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.mayocp.2019.02.003_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nri2103","article-title":"Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in\u00a0vivo","volume":"7","author":"Villadangos","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.02.003_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-017-1802-y","article-title":"Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration","volume":"135","author":"Small","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.02.003_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/mus.26166","article-title":"Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis","volume":"58","author":"Zekeridou","year":"2018","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrn.2015.27","article-title":"Autoimmune synaptopathies","volume":"17","author":"Crisp","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"51","key":"10.1016\/j.mayocp.2019.02.003_bib17","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nmo.12030","article-title":"Gastrointestinal hypomotility with loss of enteric nicotinic acetylcholine receptors: active immunization model in mice","volume":"25","author":"Meeusen","year":"2013","journal-title":"Neurogastroenterol Motil"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.003_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM200009213431204","article-title":"Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies","volume":"343","author":"Vernino","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2019.02.003_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/archneurol.2010.51","article-title":"Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease?","volume":"67","author":"Marignier","year":"2010","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM200001063420104","article-title":"Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor","volume":"342","author":"Sillevis Smitt","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2019.02.003_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/cmi.2010.74","article-title":"Thymoma and autoimmunity","volume":"8","author":"Shelly","year":"2011","journal-title":"Cell Mol Immunol"},{"issue":"4-6","key":"10.1016\/j.mayocp.2019.02.003_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11864-008-0081-1","article-title":"Paraneoplastic syndromes in thymoma: an immunological perspective","volume":"9","author":"Nelson","year":"2008","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.02.003_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2019.02.003_bib25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.mayocp.2019.02.003_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mayocp.2019.02.003_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.003_bib30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.02.003_bib31","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"230","key":"10.1016\/j.mayocp.2019.02.003_bib34","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.mayocp.2019.02.003_bib35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.20269","article-title":"Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann Neurol"},{"issue":"36","key":"10.1016\/j.mayocp.2019.02.003_bib36","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1206790","article-title":"Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor \u03b11 subunit in small-cell lung cancer cells","volume":"22","author":"Gurrola-Diaz","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.mayocp.2019.02.003_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0000000000001721","article-title":"Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study","volume":"85","author":"Gozzard","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ana.24872","article-title":"Microtubule-associated protein 1B: novel paraneoplastic biomarker","volume":"81","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.003_bib39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.59.6.929","article-title":"Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma","volume":"59","author":"Vernino","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2019.02.003_bib40","first-page":"2042","article-title":"Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells","volume":"119","author":"Roberts","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.003_bib41","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"issue":"17","key":"10.1016\/j.mayocp.2019.02.003_bib42","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients","volume":"81","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.mayocp.2019.02.003_bib43","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","article-title":"Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients","volume":"84","author":"H\u00f6ftberger","year":"2015","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.mayocp.2019.02.003_bib44","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1212\/WNL.0000000000006435","article-title":"Paraneoplastic neuronal intermediate filament autoimmunity","volume":"91","author":"Basal","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2019.02.003_bib45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaneurol.2016.0603","article-title":"Frequency of synaptic autoantibody accompaniments and neurological manifestations of thymoma","volume":"73","author":"Zekeridou","year":"2016","journal-title":"JAMA Neurol"},{"issue":"21","key":"10.1016\/j.mayocp.2019.02.003_bib46","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1158\/1078-0432.CCR-04-0735","article-title":"Autoantibody profiles and neurological correlations of thymoma","volume":"10","author":"Vernino","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.mayocp.2019.02.003_bib47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mus.23774","article-title":"Striational antibodies in a paraneoplastic context","volume":"47","author":"McKeon","year":"2013","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaneurol.2013.592","article-title":"Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping","volume":"70","author":"Klein","year":"2013","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.02.003_bib49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/jnnp-2017-316829","article-title":"Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men","volume":"89","author":"Linnoila","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mayocp.2019.02.003_bib50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12974-015-0358-9","article-title":"\u2018Medusa head ataxia\u2019: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia, Part 3: Anti-Yo\/CDR2, anti-Nb\/AP3B2, PCA-2, anti-Tr\/DNER, other antibodies, diagnostic pitfalls, summary and outlook","volume":"12","author":"Jarius","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.mayocp.2019.02.003_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12974-015-0357-x","article-title":"\u2018Medusa head ataxia\u2019: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia, Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca\/ARHGAP26 and anti-VGCC","volume":"12","author":"Jarius","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.mayocp.2019.02.003_bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12974-015-0356-y","article-title":"\u2018Medusa-head ataxia\u2019: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia, Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj\/ITPR1 and anti-CARP VIII","volume":"12","author":"Jarius","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ana.20529","article-title":"Amphiphysin autoimmunity: paraneoplastic accompaniments","volume":"58","author":"Pittock","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.02.003_bib54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.003_bib55","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archneurol.2009.78","article-title":"Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments","volume":"66","author":"McKeon","year":"2009","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.003_bib59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaneurol.2014.488","article-title":"Abnormal neurons in teratomas in NMDAR encephalitis","volume":"71","author":"Day","year":"2014","journal-title":"JAMA Neurol"},{"issue":"17","key":"10.1016\/j.mayocp.2019.02.003_bib60","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J\u00a0Neurosci"},{"issue":"pt 1","key":"10.1016\/j.mayocp.2019.02.003_bib61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planagum\u00e0","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.02.003_bib63","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.003_bib64","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/jnnp-2017-316583","article-title":"Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients","volume":"89","author":"Iorio","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.mayocp.2019.02.003_bib65","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.4049\/jimmunol.1302911","article-title":"Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells","volume":"192","author":"Sasaki","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"pt 1","key":"10.1016\/j.mayocp.2019.02.003_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/brain\/122.1.27","article-title":"Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders","volume":"122","author":"Dalmau","year":"1999","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.mayocp.2019.02.003_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.1288","article-title":"Molecular and clinical diversity in paraneoplastic immunity to Ma proteins","volume":"50","author":"Rosenfeld","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mayocp.2019.02.003_bib68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/01.CON.0000455879.99050.26","article-title":"Paraproteinemic neuropathies","volume":"20","author":"Mauermann","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"issue":"21","key":"10.1016\/j.mayocp.2019.02.003_bib69","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-03-537506","article-title":"Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas","volume":"123","author":"Graus","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.mayocp.2019.02.003_bib70","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.003_bib71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.02.003_bib72","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000001907","article-title":"Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons","volume":"85","author":"Piepgras","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.003_bib73","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.003_bib74","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.003_bib75","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.003_bib76","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mayocp.2019.02.003_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215012","article-title":"Limbic encephalitis following immunotherapy against metastatic malignant melanoma","volume":"2016","author":"Salam","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.mayocp.2019.02.003_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J\u00a0Neuroimmunol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.003_bib79","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.mayocp.2019.02.003_bib80","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2019.02.003_bib81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.02.003_bib82","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.02.003_bib83","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mayocp.2019.02.003_bib84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"33","key":"10.1016\/j.mayocp.2019.02.003_bib85","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.mayocp.2019.02.003_bib86","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619301818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619301818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:32:03Z","timestamp":1758418323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619301818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":86,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0025619619301818"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.02.003","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}